← Sionna Therapeutics, Inc. (SION) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Sionna Therapeutics, Inc. (SION)
Pharmaceutical Preparations · market cap $249M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Sionna Therapeutics (SION) is a 41-employee clinical-stage CF company with a single disclosed pipeline asset, SION-719, currently in Phase 2. The company carries a $2B market cap against $63.3M in cash representing roughly 8.7 months of runway, with no disclosed revenue and ~$75M net loss in 2025.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SION-719 | Phase 2 | Cystic Fibrosis (CF) |
Price & technical context
3-month
-88.4%
6-month
-87.7%
12-month
-82.7%
52-wk range
$4.50–$51.04
vs 50-day MA
-68.3%
vs 200-day MA
-85.0%
Realized vol
257.2%
Max drawdown
-91.2%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SION (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.